Scientific Articlesby Voluntary Organization JBCRG
2005
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer.
Kuroi K,. Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S387-92.
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer
Ohno S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Shin E, Kaise H, Kurozumi M, Tsuda H, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
Biomed Pharmacother.2005 Oct;59 Suppl 2:S323-4.
Interim analysis of a phaseII trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breastcarcinoma
Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y,Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group (JBCRG).
Breast Cancer. 2005;12(2):99-103.